News

/News
News2018-10-11T21:33:29+00:00

FDA Accepts Recros Medica De Novo Submission for Nuvellus Focal Contouring System

Recros Medica, Inc. announced today that its de novo regulatory submission for the Nuvellus™ Focal Contouring System has been accepted for review by the US Food and Drug Administration (FDA). Nuvellus™, which utilizes the company’s proprietary Rotational Fractional Resection (RFR) technology, may provide medical aesthetic physicians a minimally-invasive single treatment option to improve submental (neck and jowl) contouring.

This website uses cookies and third party services. Ok